Apyx Medical (NASDAQ: APYX) is one of 119 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare Apyx Medical to similar businesses based on the strength of its profitability, valuation, risk, earnings, institutional ownership, analyst recommendations and dividends.
This table compares Apyx Medical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Apyx Medical Competitors||-29.26%||-40.61%||-15.82%|
Volatility & Risk
Apyx Medical has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Apyx Medical’s peers have a beta of 1.11, indicating that their average share price is 11% more volatile than the S&P 500.
Valuation and Earnings
This table compares Apyx Medical and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Apyx Medical||$38.88 million||-$5.06 million||-37.65|
|Apyx Medical Competitors||$1.52 billion||$155.88 million||-189.11|
Apyx Medical’s peers have higher revenue and earnings than Apyx Medical. Apyx Medical is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
39.1% of Apyx Medical shares are owned by institutional investors. Comparatively, 50.8% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 5.7% of Apyx Medical shares are owned by company insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current ratings for Apyx Medical and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Apyx Medical Competitors||742||2667||4840||240||2.54|
Apyx Medical currently has a consensus price target of $10.00, suggesting a potential upside of 56.25%. As a group, “Surgical & medical instruments” companies have a potential upside of 379.89%. Given Apyx Medical’s peers higher probable upside, analysts plainly believe Apyx Medical has less favorable growth aspects than its peers.
Apyx Medical peers beat Apyx Medical on 7 of the 13 factors compared.
Apyx Medical Company Profile
Apyx Medical Corporation provides products in the cosmetic and surgical markets worldwide. The company markets Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. Its Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and the J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.